CN1824647A - (±)2-(二甲基氨基)-1-{[0-(m-甲氧基苯乙基)苯氧基]甲基}乙基氢琥珀酸酯盐酸盐的晶体 - Google Patents
(±)2-(二甲基氨基)-1-{[0-(m-甲氧基苯乙基)苯氧基]甲基}乙基氢琥珀酸酯盐酸盐的晶体 Download PDFInfo
- Publication number
- CN1824647A CN1824647A CN 200610004173 CN200610004173A CN1824647A CN 1824647 A CN1824647 A CN 1824647A CN 200610004173 CN200610004173 CN 200610004173 CN 200610004173 A CN200610004173 A CN 200610004173A CN 1824647 A CN1824647 A CN 1824647A
- Authority
- CN
- China
- Prior art keywords
- crystal
- peak
- spectrum
- dimethylamino
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 282
- POQBIDFFYCYHOB-UHFFFAOYSA-N Sarpogrelate hydrochloride Chemical compound Cl.COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 POQBIDFFYCYHOB-UHFFFAOYSA-N 0.000 title 1
- 238000001228 spectrum Methods 0.000 claims abstract description 97
- 238000000862 absorption spectrum Methods 0.000 claims abstract description 46
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 claims abstract description 44
- 239000007787 solid Substances 0.000 claims abstract description 44
- 239000000126 substance Substances 0.000 claims abstract description 28
- LOLKAJARZKDJTD-UHFFFAOYSA-N butanedioic acid monoethyl ester Natural products CCOC(=O)CCC(O)=O LOLKAJARZKDJTD-UHFFFAOYSA-N 0.000 claims description 127
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 88
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 75
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 73
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 68
- 238000004519 manufacturing process Methods 0.000 claims description 61
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 58
- 150000002148 esters Chemical class 0.000 claims description 53
- 239000000470 constituent Substances 0.000 claims description 47
- 239000002904 solvent Substances 0.000 claims description 46
- 238000010521 absorption reaction Methods 0.000 claims description 42
- -1 ester hydrochloride Chemical class 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 12
- 239000012190 activator Substances 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000001435 Thromboembolism Diseases 0.000 claims description 11
- 230000002490 cerebral effect Effects 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 230000000302 ischemic effect Effects 0.000 claims description 11
- 230000002792 vascular Effects 0.000 claims description 11
- 206010008118 cerebral infarction Diseases 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 208000005189 Embolism Diseases 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 208000007514 Herpes zoster Diseases 0.000 claims description 6
- 206010022562 Intermittent claudication Diseases 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 6
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 231100000397 ulcer Toxicity 0.000 claims description 6
- 201000006474 Brain Ischemia Diseases 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 5
- 230000002123 temporal effect Effects 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims 2
- FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 abstract 2
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 58
- 239000000243 solution Substances 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 238000002386 leaching Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000005384 cross polarization magic-angle spinning Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- YAVVGPBYBUYPSR-UHFFFAOYSA-N benzene;oxygen Chemical compound [O].C1=CC=CC=C1 YAVVGPBYBUYPSR-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
4.749.5210.21112.2412.6813.7814.315.115.64 | 16.1417.1417.4618.318.4818.7619.1219.4819.720.08 | 20.420.7821.0221.2621.622.1622.422.722323.32 | 23.7624.2424.424.5824.8425.2625.5425.8426.0426.68 | 26.9627.5227.7428.328.5428.8629.5429.8830.1830.6 | 30.9831.431.6632.632.9433.3635.3435.84 |
4.629.2610.1210.6612.8412.9813.914.4615.0815.66 | 16.1816.4417.2618.118.5819.119.6819.8420.2220.84 | 21.3421.6621.9622.1622.4423.1423.4224.0824.424.66 | 24.8625.326.126.5626.7426.8828.328.8229.1629.5 | 30.1230.731.131.4231.632.4632.7633.1433.3634.88 | 35.2635.536.2436.7636.9837.2838.0238.1438.9239.48 |
4.569.189.4210.1810.610.9612.7812.913.714.36 | 1515.616.1216.417.181818.518.9619.5820.14 | 20.7821.1221.4621.8422.0622.3622.723.123.3623.72 | 24.0224.3224.5825.2225.825.926.4826.7827.4827.66 | 28.228.7229.0629.4430.0430.631.3231.7231.7632.38 | 32.9836.939.42 |
175.685173.510159.212158.091146.410130.987128.537120.626113.345 | 110.39469.52468.77068.15066.68166.04365.12658.31857.072 | 53.52044.94839.49436.75937.28632.93032.58531.77430.276 |
176.093174.418172.943158.703155.841145.009 | 129.715121.219117.265112.225106.30968.589 | 65.21158.53753.40844.36838.31332.18330.522 |
175.264173.407158.689155.824146.033144.925129.712121.147117.234 | 113.149112.111109.946106.37468.67365.2556.71953.39444.349 | 39.14438.24137.03131.94230.352 |
Claims (65)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005044896 | 2005-02-22 | ||
JP2005044896 | 2005-02-22 | ||
JP2005-044896 | 2005-02-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1824647A true CN1824647A (zh) | 2006-08-30 |
CN1824647B CN1824647B (zh) | 2011-04-20 |
Family
ID=36935512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100041736A Active CN1824647B (zh) | 2005-02-22 | 2006-02-22 | (±)2-(二甲基氨基)-1-{[O-(m-甲氧基苯乙基)苯氧基]甲基}乙基氢琥珀酸酯盐酸盐的晶体 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2010077155A (zh) |
CN (1) | CN1824647B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101967104A (zh) * | 2008-11-10 | 2011-02-09 | 上海密江国际贸易有限公司 | Iv型结晶、制备该结晶的方法以及含有该结晶的药物组合物 |
CN111320601A (zh) * | 2018-12-13 | 2020-06-23 | 中国药科大学 | 一种千层纸素晶型及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5832847A (ja) * | 1981-08-20 | 1983-02-25 | Mitsubishi Chem Ind Ltd | (3−アミノプロポキシ)ビベンジル類 |
JPS61171460A (ja) * | 1985-01-23 | 1986-08-02 | Dainippon Pharmaceut Co Ltd | 塩酸メクロフエノキサ−ト1型結晶の製造法 |
DE4130173A1 (de) * | 1991-09-11 | 1993-03-18 | Bayer Ag | Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters |
JP2000219626A (ja) * | 1999-01-29 | 2000-08-08 | Mitsubishi Chemicals Corp | ケロイドおよび/または肥厚性瘢痕の治療剤 |
HRP20000328A2 (en) * | 2000-05-19 | 2002-02-28 | Pliva Farmaceutska Ind Dionik | Novel polymorph v of torasemide |
-
2006
- 2006-02-22 CN CN2006100041736A patent/CN1824647B/zh active Active
-
2009
- 2009-12-03 JP JP2009275342A patent/JP2010077155A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101967104A (zh) * | 2008-11-10 | 2011-02-09 | 上海密江国际贸易有限公司 | Iv型结晶、制备该结晶的方法以及含有该结晶的药物组合物 |
CN111320601A (zh) * | 2018-12-13 | 2020-06-23 | 中国药科大学 | 一种千层纸素晶型及其制备方法 |
CN111320601B (zh) * | 2018-12-13 | 2022-12-13 | 中国药科大学 | 一种千层纸素晶型及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2010077155A (ja) | 2010-04-08 |
CN1824647B (zh) | 2011-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1146567C (zh) | 奥氮平二水合物d | |
CN1198613C (zh) | 氨基苯氧基乙酸衍生物和含有它们的药用组合物 | |
CN1043639C (zh) | 新的哌啶化合物、其制备方法和含有它们的药用组合物 | |
CN1263755C (zh) | 作为选择性cox-2抑制剂的吡唑并吡啶衍生物 | |
CN1027068C (zh) | α-取代的4-(喹啉-2-基-甲氧基)苯乙酸和酯的制备方法 | |
CN1699343A (zh) | 盐酸多奈哌齐的多晶型物及其制备方法 | |
CN1890218A (zh) | 微管蛋白抑制剂 | |
CN1476434A (zh) | 新化合物 | |
CN1056684A (zh) | 异唑-4-羧酰胺及羟基亚烷基氰乙酰胺,含有这些化合物的药物及它们的应用 | |
CN1122036C (zh) | 用于制备奥氮平的中间体和方法 | |
CN1516699A (zh) | 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的多晶型物 | |
CN1073166A (zh) | 羟肟酸衍生物 | |
CN101052631A (zh) | 结晶霉酚酸钠 | |
CN1068820A (zh) | (s)(+)-2-乙氧基-4-[n-[1-(2-哌啶子基-苯基)-3-甲基-1-丁基]氨基羰基甲基]苯甲酸,含该化合物的药物组合物及其制备方法 | |
CN1055182A (zh) | N-(吡咯并《2,3-d》嘧啶-3-基酰基)-谷氨酸衍生物 | |
CN1646531A (zh) | 作为髓过氧化物酶抑制剂的硫代黄嘌呤衍生物 | |
CN1320123A (zh) | 二取代马来酰亚胺化合物及其医药用途 | |
CN1277820C (zh) | 作为单胺氧化酶b的抑制剂的邻苯二甲酰亚氨基衍生物 | |
CN1732173A (zh) | 高纯酞衍生物及其制备方法 | |
CN1031532A (zh) | 杂环化合物 | |
CN1092059A (zh) | 取代苯甲酸 | |
CN1173175A (zh) | 取代的2-芳基羰氧基甲基-1,2,5-噻二唑烷-3-酮1,1-二氧化物衍生物和组合物及其使用方法 | |
CN1993350A (zh) | 苯并咪唑衍生物与胺形成的盐及其制备方法 | |
CN1099752A (zh) | 新型酰氨烷基-和亚氨烷基-哌嗪 | |
CN1024790C (zh) | 尿素衍生物及其盐的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TANADE SEIYAKU CO., LTD. Free format text: FORMER OWNER: MITSUBISHI PHARMACEUTICAL CORP. Effective date: 20080815 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080815 Address after: Osaka Japan Applicant after: Tanabe Seiyaku Co.,Ltd. Address before: Osaka Japan Applicant before: MITSUBISHI PHARMA Corp. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180608 Address after: No. 16 micro three road, Microelectronics Industrial Zone, Xiqing port, Tianjin Patentee after: TIANJIN TIANBIAN PHARMACEUTICAL CO.,LTD. Address before: Osaka Japan Patentee before: MITSUBISHI TANABE PHARMA Corp. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 16 Weisan Road, Microelectronics Industrial Zone, Jingang Road, Xiqing District, Tianjin 300385 Patentee after: Yuanda Pharmaceutical (Tianjin) Co.,Ltd. Country or region after: China Address before: No. 16 Weisan Road, Microelectronics Industrial Zone, Jingang Road, Xiqing District, Tianjin 300385 Patentee before: TIANJIN TIANBIAN PHARMACEUTICAL CO.,LTD. Country or region before: China |